IBDCNC retweeted
The Women’s Policy Centre strongly opposes the appointment of the Islamic regime of Iran to key organ at the @UN shaping priorities on women's rights and terrorism prevention. We are calling on @AnitaAnandMP @MarkJCarney to reverse course. Canada can stop this travesty as @HillelNeuer rightly points out.
nationalpost.com/opinion/hil…
IBDCNC retweeted
The UN are clearly UNfit for women.
We are dismayed (to say the very least) that they would even consider a country such as Iran as a member of any body that plays a role in shaping women's rights.
Iran oppresses women and girls. They oppress the female sex. We'll take no lectures from the UN on the rights of women while they even entertain this.
nationalpost.com/opinion/hil…
The Women’s Policy Centre strongly opposes the appointment of the Islamic regime of Iran to key organ at the @UN shaping priorities on women's rights and terrorism prevention. We are calling on @AnitaAnandMP @MarkJCarney to reverse course. Canada can stop this travesty as @HillelNeuer rightly points out.
nationalpost.com/opinion/hil…
IBDCNC retweeted
Two key studies in #IBD exploring elective appendectomy in the management of #UlcerativeColitis:
• ACCURE (2025)
• COSTA (2026)
Key differences summarized below 👇
IBDCNC retweeted
Anemia is easy to miss: in the Italian SIGENP registry (JPGN), more than 1 in 3 children had anemia at IBD diagnosis, severe anemia was more common in UC than Crohn disease, and 1 in 4 was still anemic a year later. #IBD #PedsIBD
doi.org/10.1002/jpn3.70029
IBDCNC retweeted
Why do some UC patients fail vedolizumab (VDZ)?
A landmark study in Nature Medicine by Schreiber et al. unpacks the biological mechanism of VDZ resistance: revealing an alternative vascular bypass that might be targetable with common medications
IBDCNC retweeted
Replying to @IBDGastroDocSg @Nature
IBDCNC retweeted
When is it safe to de-escalate upadacitinib from 45 mg in UC?
In our newly published study, clinical and biochemical remission—not duration of induction—predicted successful dose de-escalation.
Treat the patient, not the calendar. 🎯
Read more: doi.org/10.1093/crocol/otag1…
IBDCNC retweeted
✂️ Cut, don't stretch? First RCT of stricturotomy vs balloon dilation in Crohn's Disease
📍 BEST-CD: 106 adults with short (<3 cm) symptomatic CD strictures, randomised 1:1 to endoscopic balloon dilation (EBD) or endoscopic stricturotomy (ES)
🎯 Clinical recurrence at 1 year: 30.1% with ES vs 54.7% with EBD (p=0.01)
🔁 Reintervention: 24.5% vs 49.1% · Emergency visits: 18.9% vs 50.9% · Hospitalisation: 15.1% vs 34%
🔪 Surgery 1.9% vs 11.3% (NS) · Adverse events similar (13.2% vs 22.6%)
⚠️ Expert-centre data, 1-year follow-up: needs multicentre validation
👇 The data in one image
🔗 doi.org/10.1016/j.cgh.2026.1…
#MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #Endoscopy
IBDCNC retweeted
Skin matters too: a meta-analysis of children with IBD on anti-TNF therapy found paradoxical psoriasis in 6.8% (pooled, 13 studies), and most reported cases (79.1%) were on infliximab. A big reason I co-founded our IBD-Dermatology Clinic. #IBD #PedsIBD
doi.org/10.1111/ajd.14526
IBDCNC retweeted
Calprotectin could be useful in identifying at-risk individuals before #Crohnsdisease develops
Dan Turner and colleagues propose a framework for identifying high-risk participants for prevention trials based on the PIONIR study
👇👇👇
📝 #GUTBlog | Could screening help pave the way for Crohn’s disease prevention?
Turner et al explore how faecal calprotectin can help define preclinical stages of Crohn’s disease in asymptomatic first-degree relatives, proposing a screening framework to support future prevention trials.
📄 "Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials"
📝 Read the #GUTBlog: bit.ly/3UkCNxM
🔗 Read the paper in Gut: bit.ly/4zLZWYY
#CrohnsDisease #IBD #FaecalCalprotectin #PreventionResearch
IBDCNC retweeted
Evolution of treatment targets in #IBD:
👉Stride 1 (2015)
👉Stride 2 (2021)
👉Stride 3 (2026)
Key differences, all in one table 👇
IBDCNC retweeted
Pearls of management and approach to the refractory IBD. Dr. Rubin @IBDMD #IBDSUMMIT
IBDCNC retweeted
Gilead has just paid $1.275bn for an oral IL-23 receptor peptide to pair with its own oral α4β7.
J&J is betting its oral IL-23 receptor peptide wins on its own.
Who's right?
My view: the new IBD tablets will be licensed alone. But outside the US, most will only be worth paying for in combination.
This is where each one acts in the gut wall. The best pairs hit different mechanisms, not the same one twice.
Combination therapy in IBD, Part 2: is an IBD polypill realistic? Tomorrow on Atomic IBD.
IBDCNC retweeted
Eight years ago I had the idea of combining ustekinumab and vedolizumab after anti-TNF failure in Crohn's disease. Each drug alone only went so far. Would the two together do better?
At UEG Week, Remo Panaccione presented the first data on ABBV-466, AbbVie's combination of risankizumab with trosunilimab, a new anti-α4β7 antibody.
Trosunilimab isn't vedolizumab, and it isn't a biosimilar of it. It's a new human antibody that AbbVie first developed for HIV research. In their lab work it binds α4β7 about 13 times more tightly than a comparator built from published sequences.
So α4β7 is back as a target in Crohn's disease, this time as a partner for IL-23 blockade.
AbbVie's tissue data, not yet published, show why that might work. In CD tissue, the IL-23 receptor and α4β7 sit on mostly different cells. Risankizumab alone leaves most of the gut-homing cells untouched.
The trial was part of the TARGET-CD platform study. It took 300 adults with moderate to severe CD, and three quarters had already failed an advanced therapy. They were randomised to risankizumab, trosunilimab or both (ABBV-466).
Endoscopic remission at week 12 was 30% on the combination, against 21% and 18% on each drug alone. By week 24 it was 41% against 22% and 20%. The combination almost doubled the rate and was still climbing, while each drug alone had levelled off. By week 24, more than half on the combination had an endoscopic response. The pattern held in people who had already failed an advanced therapy: 40% against 21% and 13% at week 24.
Early transcriptomics from small biopsy subsets look interesting too. Epithelial repair and barrier genes rose by week 12, and tissue repair, nerve growth and vitamin transport genes by week 24, mainly on the combination.
Safety looked similar across the three arms.
It's phase 2a and open-label. The only p-value is nominal, at week 24. Clinical remission wasn't presented, and the doses haven't been disclosed. But AbbVie is already running a blinded phase 2 platform study in around 2,000 people with CD and UC, which includes ABBV-466 at two doses. The harder test is under way.
I should have run that study eight years ago. Of course, no one would have funded it back then!
IBDCNC retweeted
Dual advanced therapy for refractory IBD: in our cohort of 30 children and young adults, all 11 on ustekinumab plus tofacitinib reached remission. Stepping down was harder: 6 of 10 lost it, but all 4 who re-intensified regained it. #IBD #PedsIBD
doi.org/10.1007/s10620-024-0…
IBDCNC retweeted
Is proximal small bowel Crohn worse than distal bcs the Tx is less effective there?
Well, No...
In our @sheba_medical #capsule study now published in @AGA_CGH , biologics induced similar mucosal healing in proximal vs distal SB.
@OffirU @HelmsleyTrust
cghjournal.org/article/S1542…
































